This article was originally published in The Gray Sheet
Executive SummaryProposed secondary offering of 3.2 mil. shares of common stock includes 2.5 mil. shares to be offered by the company and 700,000 shares to be offered by certain selling shareholders. A portion of the proceeds will be used to continue development of the Aegis Vortex atherectomy system to open coronary bypass grafts, conduct clinical trials and complete regulatory submissions for the device (1"The Gray Sheet" Aug. 16, 1999, p. 8). Funds will also be used for debt repayment and general corporate purposes. Prudential Vector Healthcare Group is lead manager of the offering; PaineWebber and Warburg Dillon Read will act as co-managers
You may also be interested in...
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.
At the OurCrowd Global Investor Summit, in Jerusalem, Israel, on 13 February, Medtech Insight met with start-up Sweetch, which has developed a personalized digital health coach for wellness and disease management.